Here is how BioNTech SE Sponsored ADR (BNTX) and EUROFINS SCIENT (ERFSF) have performed compared to their sector so far this year.

BioNTech (BNTX) is a stock many investors are watching right now. BNTX is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. We should also highlight that BNTX has a P/B ratio of 1.21.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

In trading on Tuesday, shares of BioNTech SE (Symbol: BNTX) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $87.605 per share.

According to data from Benzinga Pro, BNTX has a 52-week high of $125.83 and a 52-week low of $78.02. BNTX BioNTech SE. $111.66-% Stock Score Locked: Want to See it?

The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...

Pfizer Inc. PFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out why I rate BNTX stock a hold for now.

BioNTech SE (NASDAQ: BNTX) reported Q1 FY23 revenues of €1.28 billion, down from €6.37 billion a year ago, mainly due to lower commercial revenues from the supply and sales of the ...

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases.